The number of early phase pharmaceutical intermediate projects being outsourced by the pharma industry is increasing, thanks in part to a surge of investment about two years ago in the U.S. biotechnology sector, says Guy Villax, head of privately owned contract manufacturing organization (CMO) Hovione (Lisbon). A number of companies exhibiting...

Read the full article